Pre-market Movers For April 27 (IGTE, AAPL, DB, AMAT, CO, SOHU, CLDN, AKRX)

(RTTNews) - Gainers:

iGATE Corp. (IGTE) is gaining over 3 percent to $47.43 as Capgemini (CGEMY.PK, CAPP) has agreed to acquire the US-based technology and services company in a $4 billion deal. Capgemini has agreed to acquire IGATE for $48 per share.

Apple Inc. (AAPL) is rising over 1 percent to $132.03.

Decliners:

Deutsche Bank AG (DB) is down 4 percent to $32.78 as it reported 50 percent decline in first quarter profit, despite double-digit revenue growth, due to hefty legal charges over allegations of rate-rigging. Germany's biggest lender also announced its decisions upon the next phase of its strategy, including plan to reduce leverage in Corporate Banking & Securities, deconsolidate Postbank, invest in its transaction banking, asset and wealth management, and retail businesses.

Applied Materials, Inc. (AMAT) is falling 6 percent to $20.45 based on the news that the company and Tokyo Electron Ltd. have agreed to terminate their Business Combination Agreement as the U.S. Department of Justice has advised the parties that the coordinated remedy proposal submitted to all regulators would not be sufficient to replace the competition lost from the merger.

China Cord Blood Corp. (CO) is falling 6 percent t $6.80 based on the news that it has received a non-binding proposal letter from Golden Meditech Holdings Limited for $6.40 per ordinary share in cash.

Sohu.com Inc. (SOHU) is down 3 percent to $65.00 as it forecast second quarter revenues below Street view. The company's first quarter net loss narrowed from the year-ago quarter, while its total revenues grew 25 percent.

Celladon Corp. (CLDN) is plunging 74 percent to $3.55 after reporting that its Phase 2b CUPID2 trial did not meet its primary and secondary endpoints.

Akorn, Inc. (AKRX) is down 12 percent to $48.50 based on the news that it will restate its financial statements for the annual period ending December 31, 2014 and the quarterly periods ending June, September and December 2014 due to errors identified during the first quarter 2015 financial review process.

bluebird bio, Inc. (BLUE) is down 5 percent to $129.63.